# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney...
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announ...
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of...
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into...
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported quarterly losses of $(1.96) per share which missed the analyst consensus estimate ...